All News

celebration-315079_640.jpg

Effect of Diet on COVID Outcomes

d Jack Cush, MD

A smartphone-based symptom study of COVID-19 patients has shown that a healthy plant-based diet was associated with lower risk and severity of COVID-19, especially amongst those living in areas with higher socioeconomic deprivation.

Read Article
Pills.JIA_.png

Different Regimens but Equal Outcomes in Polyarticular JIA

d Jack Cush, MD

CARRA (Childhood Arthritis and Rheumatology Research Alliance) has compared 3 different treatment strategies for polyarticular JIA to identify the optimal time to biologic regimen.

Read Article
infection pneumonia

Pneumocystis Often Lethal in Dermatomyositis

d MedPage Today

Patients with dermatomyositis who were positive for a myositis-specific antibody had a much higher incidence of and mortality associated with Pneumocystis jirovecii infection than patients with other antibody-negative idiopathic inflammatory myopathies, Chinese researchers found.

Read Article
T2T.RA_.jpg

High Drug Switching and Low Persistence in Rheumatoid Arthritis

d Jack Cush, MD

Mease and colleagues have catalogued the current practices assessed in the CORRONA registry, noting that increased DMARD switching and decreased time on a given therapy by US physicians.

Read Article
ACR Clean (Keep)

ACR Comments on JAK Inhibitors and FDA Announcement

d ACR

Following is a statement from ACR President David Karp, MD, PhD, on JAK inhibitors and FDA drug safety communication.

Read Article
Study of 265 students w/ a positive COVID-19 test looked at 378 close contacts. Infx rates w both persons masked -7.7%, but when unmasked-32.4% (aORs = 4.9;) https://t.co/fYdH33JbWR

Links:

Dr. John Cush RheumNow ( View Tweet)

Cytokine Storm Management available for download. https://t.co/dTAzMVa6SB https://t.co/i6yo351QRN

Links:

Dr. John Cush RheumNow ( View Tweet)
Have an interest in following healthcare trends and updates on Twitter? Dr. Rachel Tate ( @uptoTate ) shared the top three healthcare hashtags to follow. #RheumNow https://t.co/pnRFNQA5BW https://t.co/5a3CzRtzwR

Links:

Dr. John Cush RheumNow ( View Tweet)
Mease and colleagues have catalogued the current practices assessed in the CORRONA registry, noting that increased DMARD switching and decreased time on a given therapy by US physicians. https://t.co/cIWZw6KsuI https://t.co/SWcedXN2jm

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR Comments on JAK Inhibitors and FDA Announcement https://t.co/zDYInRQjTl https://t.co/xu9A8I7Frs

Links:

Dr. John Cush RheumNow ( View Tweet)
Baricitinib & Tofacitinib are effective in COVID-19 pts. These drugs are expensive; baricitinib is $44/tablet, but much lower for generics worldwide. 14 day course of TOFA would be >$1,400 in the US (but $600 in France, $25 in India) https://t.co/r2cn1H2z8i

Links:

Dr. John Cush RheumNow ( View Tweet)

NICE (UK) has recommended tofacitinib as an option for treating active polyarticular juvenile arthritis and juvenile psoriatic arthritis in people 2 years and older. https://t.co/9iLqzo36aD

Links:

Dr. John Cush RheumNow ( View Tweet)

Surveys of 125 clinic patients suggests an improved pt experience by Standardizing appt phone call script, updating appointment package, include a clinic visit prep checklist, to improve pt preparedness and reduce clinic cycle time. https://t.co/5sfBFpag8V

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Causes of DYSGEUSIA (metallic taste): - Antibiotics (clarithromycin, metronidazole tetracycline), Allopurinol, captopril, Lithium, Methazolamide, Metformin, Lunesta and more... heres a video discussion on this. https://t.co/FphprLh1Sf https://t.co/1wkjQxA9UZ https://t.co/kAFaKGiHiG

Links:

Dr. John Cush RheumNow ( View Tweet)
Cytokine Storm Overview Available for Download! https://t.co/XRlx3OJDeR https://t.co/9mGnopNBTs

Links:

Dr. John Cush RheumNow ( View Tweet)
MMWR reports that during the COVID Delta variant era, Vaccination against COVID-19: - Reduces risk of COVID-19 infection 5X - Reduces risk of COVID-19 Hospitalization >10X - Reduces risk of COVID-19 DEATH 10X https://t.co/rMRY84xX5F

Links:

Dr. John Cush RheumNow ( View Tweet)

Probenecid, an OAT3 inhibitor, has inhibitory effects on RNA viruses (influenza, RSV) & decreases ACE2 expression. May have utility in COVID-19 as it was shown to inhibit SARS-CoV-2 replication in animal models https://t.co/MClSjpqpSa

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: https://t.co/wM1iRxtHvk The interleukin-6 inhibitor, tocilizumab (TCZ), was studied in a cohort of difficult systemic sclerosis (SSc) and was shown to be effective in refractory joint and skin disease with good long-term retention rates and disease stabilization. https://t.co/A8dfCksp3b

Links:

Dr. John Cush RheumNow ( View Tweet)
A retrospective study of systemic sclerosis patients shows that acute hospitalization and mortality were not uncommon and were often linked to SSc-related lung disease. #RheumNow https://t.co/s5wSlndTrt https://t.co/KHz9LYZVAK

Links:

Dr. John Cush RheumNow ( View Tweet)
J Hopkins study of 524 myositis-specific Ab positive pts shows that while 91% met 2017 EULAR/ACR criteria for Dx of myositis, 20% of HMGCR+ & 50% anti-PL7 did not classify as myositis; ~10% anti-SRP & HMGCR were dx as inclusion body myositis https://t.co/jcIn6SzbGG

Links:

Dr. John Cush RheumNow ( View Tweet)

×